Nattokinase & Arterial Plaque: The Honest Evidence

🧬 Origin & Classification

Nattokinase is a serine protease enzyme produced by the bacterium Bacillus subtilis (specifically B. subtilis var. natto) during the fermentation of soybeans into natto — a traditional Japanese food consumed for over 1,000 years. The enzyme is formally classified as subtilisin NAT, a member of the subtilisin family of proteases.

It was first identified and characterized by Dr. Hiroyuki Sumi in 1987 while researching thrombolytic enzymes at the University of Chicago. Dr. Sumi tested over 170 foods for fibrinolytic activity before discovering that natto contained the most potent natural clot-dissolving compound he had ever measured.

Nattokinase is a 275-amino-acid protein with a molecular weight of approximately 27.7 kDa. What makes it exceptional among dietary enzymes is its ability to survive gastric transit and remain biologically active in the bloodstream — a property many oral enzymes lack.

🇯🇵 Traditional Use & Epidemiological Context

Natto has been a staple of the Japanese diet — particularly in eastern Japan — for centuries. Japan has one of the lowest rates of cardiovascular disease globally, and epidemiological studies have noted an association between natto consumption and reduced cardiovascular mortality. A prospective cohort study following 29,079 Japanese adults for ~16 years — the Takayama study (Nagata et al., American Journal of Clinical Nutrition, 2017; PMID 27927636) — found that higher natto intake was significantly associated with reduced cardiovascular disease mortality.

While correlation doesn't prove causation (the Japanese diet has many cardioprotective elements), the consistency of this association across multiple studies prompted clinical investigation into isolated nattokinase supplementation.

📋 Regulatory Status

Nattokinase is classified as a dietary supplement in the United States and is not FDA-approved as a drug for treating or preventing any disease. It is available over the counter and generally recognized as safe (GRAS) in food-derived forms. In Japan, it is classified as a functional food ingredient. The Japan Nattokinase Association (JNKA) certifies quality standards for nattokinase supplements.

📊 Study Overview: n=1,062

The most-cited nattokinase plaque study (Chen et al., Frontiers in Cardiovascular Medicine, 2022; PMID 36072877) enrolled 1,062 participants and measured changes in carotid artery intima-media thickness (CIMT) and atherosclerotic plaque size over 12 months. CIMT is a validated surrogate marker for systemic atherosclerosis — thicker arterial walls and larger plaques correlate with higher cardiovascular event risk.

At a dose of 10,800 FU/day — roughly five times a typical 2,000 FU supplement — the study reported significant reductions in carotid intima-media thickness and plaque size, with "improvement rates" spanning 66.5% to 95.4%. Critically, the same study found the lower dose of 3,600 FU/day ineffective, directly challenging the dose most supplements sell.

Read this before believing the headline. This is a single study with significant conflicts of interest: several authors were employed by Sungen Bioscience (a nattokinase manufacturer) and by Sinopharm. The paper was not placebo-controlled, it carries a published erratum (Front Cardiovasc Med, Dec 2022), and the "improvement rate" metric is not the same as a clean percentage of plaque dissolved. Treat it as promising but preliminary — not proof.

🚫 The "95% Plaque Reduction" Claim — Debunked

A viral clip circulating on X (and amplified by longevity figures including David Sinclair) claims nattokinase produces "~95% plaque reduction" or "reverses arterial plaque." Here's what's actually going on:

• 🔸 The 95.4% figure is the top of a range ("improvement rates ranged from 66.5 to 95.4%"), not a uniform 95% shrinkage of everyone's plaque.
• 🔸 It comes from one industry-funded study (PMID 36072877) whose authors include employees of the supplement maker — and it has a published erratum.
• 🔸 It required 10,800 FU/day. Most "nattokinase" capsules deliver 2,000 FU, and the same study found 3,600 FU/day did nothing.
• 🔸 There is no large, independent, placebo-controlled replication confirming plaque reversal in humans.

Bottom line: nattokinase is a legitimate fibrinolytic enzyme with real cardiovascular signals (especially for blood pressure — see below), but "dissolves 95% of arterial plaque" is marketing-grade overreach, not an established clinical fact.

🔍 What the Pooled Evidence Says

A 2023 systematic review and meta-analysis of randomized controlled trials (Li et al., Reviews in Cardiovascular Medicine, 2023; PMID 39076715) pooled 6 RCTs with 546 participants (PROSPERO CRD42022315020). Its strongest, most reproducible finding was on blood pressure, not plaque — nattokinase significantly lowered systolic and diastolic pressure (detailed in the next section). Notably, it found no consistent lipid-lowering benefit at low doses, and even a small rise in blood glucose. The authors concluded nattokinase is a reasonable adjunct for hypertension, while calling for more work on whether its effects are dose-dependent.

📉 Clinical Blood Pressure Data

A randomized, double-blind, placebo-controlled trial (Kim et al., Hypertension Research, 2008; PMID 18971533) enrolled 86 participants with borderline or mild hypertension. After 8 weeks of nattokinase supplementation (2,000 FU/day), the treatment group showed:

These reductions are clinically meaningful. A 5 mmHg systolic reduction is associated with approximately a 10% reduction in cardiovascular event risk at a population level. While modest compared to prescription antihypertensives, this effect is notable for a dietary supplement.

Confirmed by pooled data The blood-pressure signal is the part of nattokinase's profile that holds up across studies. The 2023 meta-analysis of 6 RCTs (n=546; PMID 39076715) found a pooled reduction of −3.45 mmHg systolic (95% CI −4.37 to −2.18) and −2.32 mmHg diastolic (95% CI −2.72 to −1.92), both highly significant. The pooled effect is smaller than any single trial — which is exactly what you'd expect from honest meta-analysis — but it's consistent and reproducible.

🔬 Mechanism: Natural ACE Inhibition

Nattokinase inhibits angiotensin-converting enzyme (ACE) in a similar mechanism to pharmaceutical ACE inhibitors (enalapril, lisinopril, ramipril). However, nattokinase's ACE inhibition is considerably weaker than prescription medications — it should be viewed as a complementary approach, not a replacement for prescribed antihypertensives.

A 2016 study in the International Journal of Molecular Sciences confirmed nattokinase's ACE-inhibitory peptides and noted additional vasodilatory effects through prostaglandin pathways, suggesting the blood pressure reduction involves multiple mechanisms beyond ACE inhibition alone.

✈️ Deep Vein Thrombosis (DVT) Prevention

An often-cited randomized controlled trial in Angiology (the LONFLIT-FLITE study, 2003) studied clot risk in long-haul air travelers and reported fewer thrombotic events in the supplemented group. Honest caveat — that trial used a combination product (nattokinase plus Pycnogenol), so the benefit can't be attributed to nattokinase alone. It's supportive context, not clean nattokinase-only evidence.

What is well established is the mechanism: oral nattokinase survives gastric transit, reaches the bloodstream in active form, and measurably lowers D-dimer (a marker of clot turnover). A 2021 real-world safety analysis in patients with vascular disease (Nutrients; PMID 34199189) found no notable adverse events at supplemental doses, supporting its tolerability — though tolerability is not the same as proven event reduction.

🧠 Stroke Prevention & Neuroprotection

Approximately 87% of all strokes are ischemic — caused by blood clots blocking cerebral arteries. By reducing clot formation (anti-platelet activity) and enhancing clot dissolution (fibrinolysis), nattokinase addresses two of the core mechanisms of ischemic stroke.

Animal studies have demonstrated that nattokinase administration reduced infarct volume (area of brain tissue death) in experimental stroke models. While direct human stroke prevention data is limited, the aggregate of its anti-thrombotic, blood pressure-lowering, and anti-inflammatory effects supports a cardio-cerebrovascular protective profile.

This neuroprotective angle is particularly relevant to anyone building a brain protection stack. Nattokinase pairs well with omega-3 fatty acids, which reduce neuroinflammation, and compounds like lion's mane that support nerve growth factor production. See our Anti-Dementia Stack guide for a complete protocol.

💊 Nattokinase vs. Pharmaceutical Blood Thinners

Educational comparison only — NOT a recommendation to substitute

Nattokinase is sometimes compared to prescription anticoagulants like warfarin, aspirin, or clopidogrel. Here's how they differ:

Warfarin works by inhibiting vitamin K-dependent clotting factors (II, VII, IX, X). It prevents new clot formation but doesn't dissolve existing clots. Nattokinase both prevents new clots AND dissolves existing fibrin.

Aspirin irreversibly inhibits COX-1 in platelets, reducing thromboxane A2 and platelet aggregation. Nattokinase achieves similar anti-platelet effects through a different mechanism.

However, pharmaceutical anticoagulants are far more potent and predictable than nattokinase. They are prescribed for specific clinical indications (atrial fibrillation, mechanical heart valves, post-surgical prophylaxis) where consistent, dose-controlled anticoagulation is critical. Nattokinase has not been validated as a substitute for prescription anticoagulants in these high-risk scenarios.

🤝 Can You Take Both?

Many supplements combine nattokinase + serrapeptase in a single product ("systemic enzyme" formulas). The rationale is complementary mechanisms: nattokinase for clot dissolution and cardiovascular protection, serrapeptase for inflammation and tissue debris clearance.

While this combination is widely used, there is limited clinical data on the specific combination. The theoretical basis is sound, but if you're taking blood thinners, the combined anti-platelet effects require extra caution. As always, consult a physician before stacking proteolytic enzymes with anticoagulant medications.

📐 Understanding FU (Fibrinolytic Units)

Nattokinase potency is measured in FU — fibrinolytic units. This measures the enzyme's actual biological activity (how much fibrin it can dissolve), not just the weight of the powder. This is similar to how other enzymes are standardized by activity rather than mass.

1 FU = the amount of nattokinase needed to generate 1 µg of plasmin activity under standardized assay conditions. The Japan Nattokinase Association (JNKA) has established testing protocols to ensure consistent FU measurement across products.

When buying nattokinase, always check the FU count, not just the milligram weight. A 100mg capsule with 2,000 FU is more potent than a 200mg capsule with 1,000 FU. The activity is what matters.

🧮 Quick Reference

Standard dose: 2,000 FU/day   Upper range: 4,000 FU/day   Empty stomach for absorption

Need help calculating your stack doses? Try our Dosing Calculator.

Additional Safety Considerations

• Bleeding disorders: Nattokinase is contraindicated in people with hemophilia, von Willebrand disease, or other bleeding disorders. The enzyme's fibrinolytic activity poses unacceptable risk.
• Pregnancy & breastfeeding: Insufficient safety data. Avoid nattokinase during pregnancy and lactation unless specifically directed by a physician.
• Low blood pressure: Nattokinase's ACE-inhibiting and vasodilatory effects may cause excessive blood pressure drops in people with already-low BP. Monitor symptoms (dizziness, lightheadedness).
• GI upset: Some users report mild nausea, diarrhea, or stomach discomfort — typically transient and dose-related. Starting with a lower dose and titrating up may help.
• Soy allergy: Nattokinase is derived from soy fermentation. While the enzyme itself is highly purified, trace soy proteins may be present. Individuals with severe soy allergies should exercise caution or choose soy-free formulations (some manufacturers produce nattokinase via non-soy fermentation substrates).

1. Chen H, Chen J, Zhang F, et al. Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants. Front Cardiovasc Med. 2022;9:964977. PMID 36072877 · Note: industry-funded (Sungen Bioscience, Sinopharm), not placebo-controlled, carries a published erratum (Front Cardiovasc Med. 2022;9:1076420).
2. Li X, Long J, Gao Q, et al. Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Rev Cardiovasc Med. 2023;24(8):234. PMID 39076715 · 6 RCTs, n=546; pooled SBP −3.45 / DBP −2.32 mmHg.
3. Kim JY, Gum SN, Paik JK, et al. Effects of nattokinase on blood pressure: a randomized, controlled trial. Hypertens Res. 2008;31(8):1583-1588. PMID 18971533
4. Nagata C, Wada K, Tamura T, et al. Dietary soy and natto intake and cardiovascular disease mortality in Japanese adults: the Takayama study. Am J Clin Nutr. 2017;105(2):426-431. PMID 27927636
5. Gallelli G, Di Mizio G, Palleria C, et al. Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases. Nutrients. 2021;13(6). PMID 34199189